HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

HC Wainwright reissued their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock.

GANX has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a report on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Wednesday, August 14th.

Gain Therapeutics Stock Performance

GANX stock opened at $1.82 on Monday. Gain Therapeutics has a one year low of $0.89 and a one year high of $5.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The firm has a market cap of $48.27 million, a price-to-earnings ratio of -1.65 and a beta of 0.33. The firm has a 50-day simple moving average of $2.07 and a two-hundred day simple moving average of $1.72.

Hedge Funds Weigh In On Gain Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GANX. Hohimer Wealth Management LLC acquired a new position in Gain Therapeutics in the 2nd quarter worth approximately $422,000. Warberg Asset Management LLC acquired a new position in Gain Therapeutics in the 2nd quarter worth approximately $66,000. Renaissance Technologies LLC increased its holdings in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.